Roche buys US biotech firm InterMune for £5bn

Filling syringes

Related Stories

Swiss pharmaceutical giant Roche has said it will buy maker of lung disease therapies InterMune for $8.3bn (£5bn).

Intermune, which is based in Brisbane, California, makes a medicine for idiopathic pulmonary fibrosis, a deadly disease which scars the lungs.

The deal is the latest in a string of mergers in the drugs sector.

It is also the largest by Roche since 2009 when it bought the remainder of Genentech for about $47bn.

Pharmaceutical mergers

Roche will pay $78 per share in InterMune, which is a premium of 38% on top of the value of the shares at the end of last week.

Recent deals in the drug sector include US drug firm AbbVie's purchase of the UK pharmaceutical company Shire for £32bn.

UK High Street chemist Alliance Boots was bought up by US pharmacy giant Walgreens in an agreement earlier this month.

In May, pharmaceutical company Pfizer dropped a bid for UK company AstraZeneca.

More on This Story

Related Stories

From other news sites

* May require registration or subscription

More Business stories

RSS

BBC Business Live

  1.  
    06:28: GLAXOSMITHKLINE Radio 5 live

    Newspapers are reporting GlaxoSmithKline may spin off its HIV business. Holly Cook, managing editor of Morningstar's website for UK investors tells 5 liveWake Up to MoneyGSK's respiratory drug, advair is under "intense competition" and a sale through a public offer "will allow GSK to streamline itself" as its HIV drugs see "huge demand".

     
  2.  
    06:15: TESCO EARNINGS Radio 5 live

    "Like-for-like sales is the first number analysts will look at, followed by the accounting problems," says Holly Cook of Morningstar on Wake Up to Money. The online business may have done well while the supermarkets will be a "weak spot." Looking at Tesco, "a lot of customers find it a bit overwhelming and you are bombarded by information and you can't find what you want."

     
  3.  
    06:07: TESCO EARNINGS Radio 5 live
    A Tesco trolley

    "When the CEO is on gardening leave the chairman should step up and that's not happened," says Mr Roberts on Wake Up to Money, talking about the performance of Tesco chairman Sir Richard Broadbent. The supermarket discovered a £250m profit black hole. "I'd be remarkably surprised if it's limited to a 6-month period," he adds.

     
  4.  
    06:01: TESCO EARNINGS Radio 5 live

    Brian Roberts of Kantar Retail is on Wake Up to Money talking about Tesco's results, out today. "There's lots of hoops you have to jump through" as a shopper at Tesco, he says. Buy one get one free, the loyalty card, driving a car and buying the petrol. "With Aldi you just have to turn up... Tesco used to have the shopper at the centre of the business and now they've replaced the shopper with the shareholder."

     
  5.  
    06:00: Howard Mustoe Business reporter

    Good morning. Get in touch via email bizlivepage@bbc.co.uk and twitter @BBCBusiness

     
  6.  
    06:00: Matthew West Business reporter

    Morning all. Now we could try and pretend that there is other news going on (and in fairness there is some) but let's face it, the focus today is all going to be on Tesco's half year results. We'll bring you them as soon as they drop, plus all the reaction and the rest of the day's news as it happens.

     

Features

From BBC Capital

Programmes

  • St John's, CanadaThe Travel Show Watch

    It’s a ships’ symphony – listen to these freighters in Canada play music with their horns

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.